Alnylam endocrine/metabolic, hematology news
Alnylam said it will restructure and reduce headcount by 61 (33%) to about 115 to focus on development of its ALN-TTR and ALN-APC programs. The programs are part of Alnylam's 5x15 strategy aimed at moving five RNAi therapeutic programs into clinical development by 2015. The company said it plans to partner the remaining three programs, ALN-PCS, ALN-HPN and ALN-TMP, prior to conducting additional clinical testing. The cuts, which will come from across the company, are expected to save about $20 million in 2012.
Data from a Phase I trial of ALN-PCS in hypercholesterolemia are expected this half. ALN-HPN and ALN-TMP are in preclinical development to treat anemia and hemoglobinopathies such as beta-thalassemia and sickle cell anemia, respectively. ALN-PCS is a small interfering RNA against the proprotein convertase subtilisn/kexin type 9 ( PCSK9) gene. ALN-HPN is an RNAi therapeutic targeting the hepcidin pathway via transferrin receptor 2 (TFR2), while ALN-TMP is an RNAi targeting the transmembrane protease serine 6 ( TMPRSS6; Matriptase-2). ...